Overview

The Prevention of Osteoporosis in Premenopausal and Newly Postmenopausal (Up to 8 Years) Women With Breast Cancer Following Chemotherapy (REBBeCA Study)

Status:
Completed

Trial end date:
2006-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the effectiveness of once weekly risedronate in the prevention and treatment of bone loss in premenopausal and newly menopausal women with breast cancer who have received chemotherapy. The hypothesis is that bisphosphonate therapy will prevent bone loss at clinically relevant sites, such as the hip and spine. The investigators also hypothesize that there will be a correlation between biochemical markers of bone turnover and changes in bone mineral density.

Phase:

N/A

Details

Lead Sponsor:

University of Pittsburgh

Collaborators:

Aventis Pharmaceuticals
Procter and Gamble

Treatments:

Risedronate Sodium
Risedronic Acid